New clinical findings at ADA 2025 highlight continued innovation and competition in obesity and diabetes treatments centered on GLP-1 receptor agonists. Amgen’s obesity drug MariTide showed notable weight loss but high discontinuation rates linked to gastrointestinal side effects, prompting plans for slower dosing in Phase 3. Novo Nordisk’s CagriSema displays weight loss comparable to competitors but questions remain on plateau effects and dosing. Eli Lilly’s bimagrumab combined with Wegovy preserves lean mass while enhancing fat loss. Additionally, novel oral drugs with different mechanisms are emerging as alternatives to injectable GLP-1s. Meanwhile, regulatory and commercial disruptions continued with Novo ending its deal with telehealth company Hims over compounded drug concerns.